Summary
Follow-up data of 113 patients with stage IV breast cancer treated with the antiestrogen tamoxifen show that the duration of remission is in average in excess of 21 months with a median of 16 months. Survival from start of antiestrogen therapy was significantly longer in patients who responded to tamoxifen, in those with dominant site of disease in the soft tissue, and in those with less extensive metastatic involvement. Overall survival from onset of metastasis was also much longer in patients who had responded to tamoxifen than in those who had failed (median of 52 and a half months vs 23 months). Hypophysectomy and androgen therapy used sequentially after antiestrogen each induced further remissions in almost half of the patients with a median duration of 16 months and 10 months respectively. Five drug chemotherapy used in most patients after maximum benefit had been obtained with endocrine therapy induced remissions in two-thirds of the patients with a median duration of 8 months. Adriamycin used sequentially as a single agent induced significant further palliation in almost half of the patients with a median duration of 4 and a half months. We conclude that sequential endocrine therapy and chemotherapy is highly effective in the treatment of stage IV breast cancer and offers prolonged survival to patients with hormone responsive tumors.
Similar content being viewed by others
References
Manni A, Trujillo J, Marshall JS, Brodkey J, Pearson OH: Antihormone treatment of stage IV breast cancer. Cancer 43: 444–450, 1979.
Manni A, Trujillo JE, Pearson OH: Sequential use of endocrine treatment and chemotherapy in metastatic breast cancer: effects on survival. Cancer Treat Rep 64: 111–116, 1980
Manni A, Pearson OH: Antiestrogen-induced remissions in premenopausal women with stage IV breast cancer: effects on ovarian function. Cancer Treat Rep 64: 779–785, 1980
Pritchard KI, Thomson DB, Myers RE, Sutherland DJA, Mobbs BG, Meakin JW: Tamoxifen therapy in premenopausal patients with metastatic breast cancer. Cancer Treat Rep 64: 787–796, 1980
Hubay CA, Pearson OH, Marshall JS, Rhodes RS, DeBanne SM, Rosenblatt J, Mansour EG, Hermann RE, Jones JC, Flynn WJ, Eckert C, McGuire WL, and 27 participating investigators: Adjuvant chemotherapy, antiestrogen therapy and immunotherapy for stage II breast cancer: 45-month follow-up of a prospective, randomized clinical trial. Cancer 46: 2805–8, 1980
Manni A, Trujillo J, Marshall J, Pearson OH: Antiestrogeninduced remissions in stage IV breast cancer. Cancer Treat Rep 60: 1445–1450, 1976
Manni A, Arafah BM, Pearson OH: Medical hypophysectomy in advanced breast cancer,In DP Rose (ed): Endocrinology of Cancer, Vol 3, CRC Press, 1981 (in press)
Arafah BM, Manni A, Pearson OH: Effect of hypophysectomy and hormone replacement on hormone receptor and the growth of 7,12-dimethyl-benz(a)anthracene-induced mammary tumors in the rat. Endocrinology 107: 1364–1369, 1980
Canellos GP, DeVita VT, Gold LH, Chabner BA, Schein PS, Young RC: Combination chemotherapy for advanced breast cancer: response and effect on survival. Ann Int Med 84: 389–392, 1976
Kenneally GT, Boston B, Mitchell MS, Knobf MK, Bobrow SN, Pezzimenti JF, Lawrence R, Bertino JR: Combination chemotherapy for advanced breast cancer. Two regimens containing Adriamycin. Cancer 42: 27–33, 1978
Author information
Authors and Affiliations
Additional information
Address for reprints: Dr. Andrea Manni, University Hospitals of Cleveland, 2074 Abington Road, Cleveland, OH 44106.
Rights and permissions
About this article
Cite this article
Manni, A., Pearson, O.H., Marshall, J.S. et al. Sequential endocrine therapy and chemotherapy in metastatic breast cancer: Effects on survival. Breast Cancer Res Tr 1, 97–103 (1981). https://doi.org/10.1007/BF01805861
Issue Date:
DOI: https://doi.org/10.1007/BF01805861